ProPhase Labs, Inc. (PRPH)
NASDAQ: PRPH · IEX Real-Time Price · USD
+0.040 (0.92%)
Jun 21, 2024, 4:00 PM EDT - Market closed

ProPhase Labs Statistics

Total Valuation

ProPhase Labs has a market cap or net worth of $83.75 million. The enterprise value is $105.30 million.

Market Cap 83.75M
Enterprise Value 105.30M

Important Dates

The next estimated earnings date is Thursday, August 8, 2024, before market open.

Earnings Date Aug 8, 2024
Ex-Dividend Date n/a

Share Statistics

ProPhase Labs has 19.08 million shares outstanding. The number of shares has decreased by -0.09% in one year.

Shares Outstanding 19.08M
Shares Change (YoY) -0.09%
Shares Change (QoQ) -0.06%
Owned by Insiders (%) 17.47%
Owned by Institutions (%) 9.10%
Float 15.73M

Valuation Ratios

PE Ratio n/a
Forward PE 10.09
PS Ratio 2.92
Forward PS 1.08
PB Ratio 1.87
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 3.67
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.52.

Current Ratio 1.88
Quick Ratio 1.54
Debt / Equity 0.52
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -19.44

Financial Efficiency

Return on equity (ROE) is -45.00% and return on invested capital (ROIC) is -45.16%.

Return on Equity (ROE) -45.00%
Return on Assets (ROA) -25.90%
Return on Capital (ROIC) -45.16%
Revenue Per Employee $254,115
Profits Per Employee -$208,823
Employee Count 113
Asset Turnover 0.32
Inventory Turnover 5.81


Income Tax -8.60M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -40.19% in the last 52 weeks. The beta is -0.17, so ProPhase Labs's price volatility has been lower than the market average.

Beta (1Y) -0.17
52-Week Price Change -40.19%
50-Day Moving Average 5.12
200-Day Moving Average 4.93
Relative Strength Index (RSI) 36.87
Average Volume (20 Days) 38,913

Short Selling Information

The latest short interest is 314,169, so 1.65% of the outstanding shares have been sold short.

Short Interest 314,169
Short Previous Month 260,065
Short % of Shares Out 1.65%
Short % of Float 2.00%
Short Ratio (days to cover) 2.61

Income Statement

In the last 12 months, ProPhase Labs had revenue of $28.72 million and -$23.60 million in losses. Loss per share was -$1.36.

Revenue 28.72M
Gross Profit 5.29M
Operating Income -30.80M
Pretax Income -32.20M
Net Income -23.60M
EBITDA -23.50M
EBIT -30.62M
Loss Per Share -$1.36
Full Income Statement

Balance Sheet

The company has $1.79 million in cash and $23.34 million in debt, giving a net cash position of -$21.54 million or -$1.13 per share.

Cash & Cash Equivalents 1.79M
Total Debt 23.34M
Net Cash -21.54M
Net Cash Per Share -$1.13
Equity / Book Value 44.87M
Book Value Per Share 2.35
Working Capital 21.14M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$16.94 million and capital expenditures -$3.53 million, giving a free cash flow of -$20.47 million.

Operating Cash Flow -16.94M
Capital Expenditures -3.53M
Free Cash Flow -20.47M
FCF Per Share -$1.14
Full Cash Flow Statement


Gross margin is 18.41%, with operating and profit margins of -107.27% and -82.18%.

Gross Margin 18.41%
Operating Margin -107.27%
Pretax Margin -112.12%
Profit Margin -82.18%
EBITDA Margin -81.85%
EBIT Margin -106.63%
FCF Margin -71.30%

Dividends & Yields

ProPhase Labs does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth 1
Payout Ratio n/a
Buyback Yield 0.09%
Shareholder Yield 0.09%
Earnings Yield -28.17%
FCF Yield -24.45%
Dividend Details

Analyst Forecast

The average price target for ProPhase Labs is $11.00, which is 150.57% higher than the current price. The consensus rating is "Strong Buy".

Price Target $11.00
Price Target Difference 150.57%
Analyst Consensus Strong Buy
Analyst Count 1
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

The last stock split was on January 23, 1997. It was a forward split with a ratio of 2:1.

Last Split Date Jan 23, 1997
Split Type Forward
Split Ratio 2:1


ProPhase Labs has an Altman Z-Score of 0.42 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 0.42
Piotroski F-Score 1